Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 study of intrathecal Salanersen in presymptomatic infants with genetically diagnosed SMA
CTR20262031Phase 3Active
- Sponsor
- 不适用/ 渤健生物科技（上海）有限公司
- Start
- Apr 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of salanersen in spinal muscular atrophy (SMA), sponsored by 不适用/ 渤健生物科技（上海）有限公司. Started Apr 2026; status: active.
02
Drugs
salanersen
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on CTR20262031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262031.